Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months.
In twenty-two patients with active acromegaly who were untreated or unsuccessfully operated or irradiated (mean growth hormone (GH) values greater than 4 ng/ml) the following investigations were performed: routine laboratory tests, tomography of pituitary fossa, oral glucose tolerance tests, TRH and other pituitary function tests and GH profiles over 5-10 h before and during bromocriptine treatment with daily doses between 7.5 and 50 mg. In seventeen patients GH was suppressed to less than 50% by bromocriptine, in thirteen of them it was normalized on at least one occasion. A TRH induced GH release was observed in all but two responders to bromocriptine before therapy. This effect of TRH was not blunted during treatment with bromocriptine and also in the two patients with negative tests before therapy a significant GH increase was observed. In no non-responder to bromocriptine was a significant increase of GH after TRH observed. One patient showed a secondary resistance to bromocriptine during a period of treatment with griseofulvin. In the remaining sixteen patients the GH suppression has been consistent for between 3 and 22 months. A single dose of pimozide abolished the bromocriptine effect on GH totally in one patient; in others a slight or no significant effect was observed. Tissue swelling and sweating decreased in all bromocriptine responders and glucose tolerance improved in five patients. In four diabetic patients a partial or full remission of diabetes occurred. Apart from postural hypotension after the first administration in two patients no other severe side effects have been observed. Sella size and the other pituitary functions did not change during the time of the study. It seems that a high percentage of acromegalics may be successfully treated with bromocriptine.
D000172:Acromegaly / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000209:etiology; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D010868:Pimozide / Q000494:pharmacology; D013973:Thyrotropin-Releasing Hormone
D004873:Ergolines; D010868:Pimozide; D001971:Bromocriptine; D013973:Thyrotropin-Releasing Hormone; D013006:Growth Hormone